Table 5.
Pharmacokinetic parameters of four compounds after an oral administration in normal rats (n = 6).
| Compound No. | Group | Cmax/ng·mL−1 | Tmax/h | T1/2/h | AUC0~t/ng·h·mL−1 |
|---|---|---|---|---|---|
| 1 | GSBXD | 503.15 ± 199.16 | 0.33 ± 0 | 5.93 ± 2.67 | 2631.14 ± 531.93 |
| GSBXD-GS | 213.90 ± 55.44 * | 1.67 ± 0.12 * | 11.56 ± 5.74 | 1278.93 ± 392.92 ** | |
| GG | 364.49 ± 46.19 | 0.64 ± 0.34 | 9.29 ± 4.70 ** | 787.72 ± 109.53 ** | |
| GC | 146.86 ± 19.86 | 0.36 ± 0.16 | 0.79 ± 0.39 | 485.51 ± 136.03 | |
| 2 | GSBXD | 192.59 ± 84.49 | 0.39 ± 0.14 | 7.04 ± 2.99 | 793.58 ± 141.51 |
| GSBXD-GS | 98.93 ± 26.76 | 0.17 ± 0.11 ** | 6.84 ± 3.11 | 421.44 ± 221.90 ** | |
| GG | 199.61 ± 42.40 | 0.32 ± 0.27 * | 12.86 ± 4.76 * | 787.72 ± 109.53 | |
| GC | 138.98 ± 33.54 | 0.50 ± 0.18 | 5.26 ± 1.93 | 797.39 ± 173.64 | |
| 3 | GSBXD | 82.79 ± 15.72 | 0.81 ± 0.34 | 12.55 ± 7.46 | 825.06 ± 96.02 |
| GSBXD-GS | 101.20 ± 17.96 | 1.33 ± 0.37 | 7.90 ± 1.17 | 909.502 ± 476.26 | |
| GSBXD-GC | 74.12 ± 25.99 | 0.31 ± 0.07 | 16.04 ± 2.62 | 362.33 ± 40.42 | |
| GSBXD-GG | 149.87 ± 24.51 # | 0.50 ± 0.28 | 21.41 ± 8.85 | 658.98 ± 411.01 | |
| 4 | GSBXD | 255.17 ± 98.01 | 0.33 ± 0.18 | 8.06 ± 1.44 | 1114.96 ± 346.19 |
| GSBXD-GS | 141.63 ± 39.84 | 0.28 ± 0.14 | 9.07 ± 0.87 | 513.95 ± 271.24 | |
| GSBXD-GC | 88.46 ± 18.26 | 0.81 ± 0.62 | 7.74 ± 0.74 | 618.64 ± 129.51 | |
| GSBXD-GG | 112.65 ± 25.78 # | 0.56 ± 0.27 ## | 8.73 ± 0.98 | 785.47 ± 158.14 |
Data are expressed as mean ± S.D. (n = 6). * Difference from corresponding GC group, p < 0.05; ** Difference from corresponding GC group, p < 0.01; # Difference from corresponding GSBXD group, p < 0.05; ## Difference from corresponding GSBXD group, p < 0.01.